Results 21 to 30 of about 473,693 (291)

Vaccination Strategies: Mixing Paths Versus Matching Tracks

Vaccines
Vaccination strategies play a pivotal role in achieving broad and robust immune protection. With the advent of new technologies and challenges posed by emerging infectious diseases such as SARS-CoV-2, evaluating the efficacy of homologous (matching ...
Achilleas Livieratos, Charalambos Gogos, Iason Thomas, Karolina Akinosoglou   +3 more
doaj   +2 more sources

Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes. [PDF]

PLoS One, 2019
Malgré les risques accrus de cancers et de maladies cardiovasculaires, le tabagisme continue d'être répandu dans la population en grande partie en raison de la nature addictive de la nicotine. Les vaccins à la nicotine sont une alternative attrayante aux options actuelles de sevrage tabagique, mais ils n'ont pas encore eu suffisamment de succès dans ...
Fraleigh NL, Oliva R, Lewicky JD, Martel AL, Acevedo R, Dagmar GR, Le HT.   +6 more
europepmc   +5 more sources

Evolution of infectious bronchitis virus in the field after homologous vaccination introduction. [PDF]

Vet Res, 2019
AbstractDespite the fact that vaccine resistance has been typically considered a rare phenomenon, some episodes of vaccine failure have been reported with increasing frequency in intensively-raised livestock. Infectious bronchitis virus (IBV) is a widespread avian coronavirus, whose control relies mainly on extensive vaccine administration ...
Franzo G, Legnardi M, Tucciarone CM, Drigo M, Martini M, Cecchinato M.   +5 more
europepmc   +7 more sources

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts

JAMA Network Open, 2022
Importance: Antibody responses elicited by current messenger RNA (mRNA) COVID-19 vaccines decline rapidly and require repeated boosting. Objective: To evaluate the immunogenicity and durability of heterologous and homologous prime-boost regimens involving the adenovirus vector vaccine Ad26.COV2.S and the mRNA vaccine BNT162b2.
Tan, C. Sabrina, Collier, Ai-ris Y., Yu, Jingyou, Liu, Jinyan, Chandrashekar, Abishek, McMahan, Katherine, Jacob-Dolan, Catherine, He, Xuan, Roy, Vicky, Hauser, Blake M., Munt, Jennifer E., Mallory, Michael L., Mattocks, Melissa, Powers, John M., Meganck, Rita M., Rowe, Marjorie, Hemond, Rachel, Bondzie, Esther A., Jaegle, Kate H., Baric, Ralph S., Schmidt, Aaron G., Alter, Galit, Le Gars, Mathieu, Sadoff, Jerald, Barouch, Dan H.   +24 more
openaire   +2 more sources

Experiments with a homologous, inactivated canine parvovirus vaccine in vaccination programmes for dogs [PDF]

Veterinary Quarterly, 1982
The significance of canine parvovirus (CPV) infections as a permanent threat susceptible dogs, in particular pups, made the authors develop three liquid homologous inactivated adjuvant CPV vaccines that were compatible with existing canine vaccines and could be incorporated in current vaccination programmes.
J H, Wilson, W M, Hermann-Dekkers
openaire   +2 more sources

Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people [PDF]

Immunity & Ageing, 2021
Abstract Background Several SARS-CoV-2 vaccines have shown clinical efficacy against Covid-19 infection but there remains uncertainty about the immune responses elicited by different regimens.
Helen Parry, Rachel Bruton, Christine Stephens, Kevin Brown, Gayatri Amirthalingam, Ashley Otter, Bassam Hallis, Jianmin Zuo, Paul Moss   +8 more
openaire   +3 more sources

Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges [PDF]

npj Vaccines, 2021
AbstractWe previously developed a temperature-sensitive, and NS1 gene deleted live attenuated influenza vaccine (DelNS1-LAIV) and demonstrated its potent protective efficacy in intranasally vaccinated mice. Here we investigated whether intradermal (i.d.) vaccination induces protective immunity.
Andrew Chak-Yiu Lee, Anna Jinxia Zhang, Can Li, Yanxia Chen, Feifei Liu, Yan Zhao, Hin Chu, Carol Ho-Yan Fong, Pui Wang, Siu-Ying Lau, Kelvin Kai-Wang To, Honglin Chen, Kwok-Yung Yuen   +12 more
openaire   +3 more sources

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review

Infectious Diseases of Poverty, 2022
Background Heterologous prime-boost with ChAdOx1 nCoV-19 vector vaccine (ChAd) and a messenger RNA vaccine (BNT or mRNA-1273) has been widely facilitating mass coronavirus disease 2019 (COVID-19) immunisation.
Jingjing Lv, Hui Wu, Junjie Xu, Jiaye Liu   +3 more
doaj   +1 more source

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection

Emerging Microbes and Infections, 2022
Given emerging evidence of immune escape in the SARS-CoV-2 Omicron viral variant, and its dominance, effectiveness of heterologous and homologous boosting schedules commonly used in low-to-middle income countries needs to be re-evaluated.
Jing Lian Suah, Boon Hwa Tng, Peter Seah Keng Tok, Masliyana Husin, Thevesh Thevananthan, Kalaiarasu M. Peariasamy, Sheamini Sivasampu   +6 more
doaj   +1 more source

Adverse events data of following the homologous and heterologous booster vaccination.

, 2023
Adverse events data of following the homologous and heterologous booster vaccination.
Carmen Valenzuela Silva (17319206), Amitis Ramezani (6329339), Alireza Biglari (12152590), Sana Eybpoosh (2826068), Anahita Bavand (6329345), Mostafa Salehi-Vaziri (6273803), Mohammad Banifazl (17319212), Sarah Dahmardeh (17319209), Vicente Verez-Bencomo (17319200), Rahim Sorouri (17319194), Maria Eugenia Toledo-Romani (17319203), Ehsan Mostafavi (406077), Mona Sadat Larijani (17319197), Delaram Doroud (348344), Fatemeh Ashrafian (9619876)   +14 more
core   +1 more source